Baseline Characteristics of the Patients - Part I

Slides:

Advertisements

Similar presentations

Sibbing D, et al. J Am Coll Cardiol 2009;53:

Advertisements

Description of Each Study in the Cross Trial Safety Analysis Solomon SD, et al. Circulation 2008 [Epub Mar 31]

Trial profile Fox K et al. Lancet 2008;372:

The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) The LIPID Study Group N Engl J Med 1998;339:

COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)

Slide Source: Primary and Other Outcomes: DREAM Rosiglitazone group (n=2635) Placebo group (n=2634)HR (95% CI)p Composite primary.

Flow Diagram of the Main HOPE Trial and the HOPE-TOO Trial Extension The HOPE and HOPE-TOO Trial Investigators JAMA. 2005;293:

Lancet 373: , 2009 Baseline Characteristics of Participants and Study Design of Clinical Trials to Compare Intensive glucose- lowering versus.

LIPID: Long-term Intervention with Pravastatin in Ischemic Disease Purpose To determine whether pravastatin will reduce coronary mortality and morbidity.

HOPE: Heart Outcomes Prevention Evaluation study Purpose To evaluate whether the long-acting ACE inhibitor ramipril and/or vitamin E reduce the incidence.

Enrollment and Outcomes Fan Fan Hou, et al. N Engl J Med 2006;354:

The ACTIVE Investigators. N Engl J Med 2009 Apr 3 [Epub]

The Heart Outcomes Prevention Evaluation (HOPE) 2 Investigators. N Engl J Med 2006; available at: End pointActive therapy PlaceboRelative.

The ILLUMINATE Study: Enrollment and Outcomes Philip Barter, et al. N Engl J Med 2007;357:

Baseline Characteristics of the Patients* - Part I The ONTARGET Investigators. N Engl J Med 2008 [Epub on Mar 31]

Enrollment and Outcomes Duckworth W, et al. N Engl J Med 2009;360:

Date of download: 6/3/2016 From: Elevated Plasma Homocysteine Level Is an Independent Predictor of Coronary Heart Disease Events in Patients with Type.

1 Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled.

Mega JL, et al. N Engl J Med 2009;360: Genetic Effects on Pharmacokinetic and Pharmacodynamic Responses to Clopidogrel Mega JL, et al. N Engl J.

Christopher P. Cannon, M. D. , Eugene Braunwald, M. D. , Carolyn H

Discontinuation of medication after nonfatal event: MI

The SPRINT Research Group

Structure of Cis and Trans Fatty Acids

Flow of Individuals Through the Vitamin E and Vitamin C Components of the Physicians’ Health Study II Howard D. Sesso et al. JAMA 2008;300:

Trial profile SAS denotes the Simvastatin in Aortic Stenosis Study

LEADER trial: Primary Outcome

Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention Trial Robert S. Bresalier, M.D., Robert S. Sandler, M.D., Hui Quan,

CORAL Trial design: Patients with renal artery stenosis and hypertension or chronic kidney disease were randomized to renal artery stenting (n = 467) vs.

HOPE: Heart Outcomes Prevention Evaluation study

EVEREST II 5-Year Report and Beyond

Characteristics of the Folic Acid and Placebo Groups at the Start of the Study J. Durga et al. Arch Intern Med. 2005;165:

TNT: Baseline and final LDL cholesterol levels

51st Annual Scientific Session for the LIFE Investigators

Western Norway B-vitamin Intervention Trial

PAD Patients vs Post-ACS Patients:

Baseline characteristics of patients

TNT Study: Baseline Characteristics of the Patients

The Hypertension in the Very Elderly Trial (HYVET)

Rounded incidence values (%) of renal and nonrenal events

Study Design Ketil Lunde, et al. N Engl J Med 2006;355:

Cardiovascular outcomes in patients with peripheral arterial disease as an initial or subsequent manifestation of atherosclerotic disease: Results from.

P2Y12 blockade versus placebo; risk ratio with 95% CIs for the primary composite end point of cardiovascular death, non-fatal myocardial infarction and.

Volume 9, Issue 9, Pages (September 2010)

Enrollment and Outcomes

Volume 371, Issue 9627, Pages (May 2008)

Trial profile GISSI-HF investigators. Lancet 2008; Aug 29 [Epub ahead of print]

Trial profile GISSI-HF investigators. Lancet 2008; Aug 29 [Epub ahead of print]

Inclusion Criteria for Patients with Multiple Atherothrombotic Risk Factors and for Those with Established Cardiovascular Disease Deepak L.Bhatt, et al,

Baseline Characteristics of the Subjects

Characteristics of the Patients at Baseline*

Volume 375, Issue 9719, Pages (March 2010)

Baseline Characteristics of the Patients and Use of Concomitant Medications – Part I Kaare Harald Bønaa, et al. N Engl J Med 2006;354:

Baseline Characteristics of the Study Participants

ACST: which subgroups will benefit most from carotid endarterectomy?

Women’s Health Study: Baseline Characteristics Part 1

Patient Disposition James A. de Lemos et al. JAMA 2004; 292:

Volume 65, Issue 4, Pages (April 2004)

Collet JP, et al. Lancet 2009;373:309-17

Entry, Randomization, and Follow-up of Patients in the Hypertension in the Very Elderly Trial Of the 461 patients who did not meet the protocol criteria,

Baseline Characteristics of Elderly Participants in the Cardiovascular Health Study,According to Quintiles of Cystatin C Michael G.Shlipak et al N Engl.

Baseline Characteristics of the Patients – Part I

RECORD Study: Enrollment and Outcomes

The ACCORD Study Group. NEJM 2010; Epub March 14

Baseline Clinical Characteristics of All Patients and Patients Grouped by Statin Therapy - Part I H. Fukuta et al. Circulation 2005;112:

Additional benefit of PCSK9 inhibition in high risk patients after myocardial infarction A FOURIER subanalysis Primary endpoint: composite of CV death,

The benefit of evolocumab treatment is consistent regardless of inflammation level HR %CI ARR 1.6% 1.8%

Baseline characteristics of study population

Representative Light Micrographs of Kidney Sections Illustrating the Histologic Scoring Criteria Giuseppe Remuzzi, et al, N Engl J Med 2006;3354:

Cardiac death, target vessel myocardial infarction (MI), target lesion revascularisation (TLR) by Kaplan-Meier method. Cardiac death, target vessel myocardial.

Prasugrel versus clopidogrel; risk ratio with 95% CIs for the primary composite end point of cardiovascular death, non-fatal myocardial infarction and.

Presentation transcript:

Baseline Characteristics of the Patients - Part I The HOPE 2 Investigators, N Engl J Med 2006;354:1567-77

Baseline Characteristics of the Patients - Part II The HOPE 2 Investigators, N Engl J Med 2006;354:1567-77

Baseline Characteristics of the Patients - Part III The HOPE 2 Investigators, N Engl J Med 2006;354:1567-77

Mean (+SD) Plasma Levels of Total Homocysteine, Folate, Vitamin B6 , and Vitamin B12 The HOPE 2 Investigators, N Engl J Med 2006;354:1567-77

Kaplan-Meier Estimates of the Proportion of Patients with the Composite Primary Outcome of Death from Cardiovascular Causes, Myocardial Infarction, or Stroke The HOPE 2 Investigators, N Engl J Med 2006;354:1567-77

Outcomes – Part I The HOPE 2 Investigators, N Engl J Med 2006;354:1567-77

Outcomes – Part II The HOPE 2 Investigators, N Engl J Med 2006;354:1567-77

Effect of Folic Acid and Vitamins B6 and B12 on the Primary Outcome in Prespecified and Exploratory Subgroups The HOPE 2 Investigators, N Engl J Med 2006;354:1567-77